Upstream Bio (UPB) to Release Earnings on Thursday

Upstream Bio (NASDAQ:UPB) is anticipated to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Upstream Bio to post earnings of ($0.56) per share for the quarter.

Upstream Bio Stock Up 3.0 %

UPB stock opened at $8.22 on Tuesday. The company has a 50-day moving average price of $12.38. Upstream Bio has a 1-year low of $6.65 and a 1-year high of $29.46.

Analysts Set New Price Targets

A number of research firms have recently issued reports on UPB. Piper Sandler started coverage on shares of Upstream Bio in a research note on Tuesday, November 5th. They set an “overweight” rating and a $75.00 price objective on the stock. William Blair began coverage on Upstream Bio in a report on Tuesday, November 5th. They issued an “outperform” rating on the stock. TD Cowen started coverage on Upstream Bio in a research note on Tuesday, November 5th. They set a “buy” rating for the company. Finally, JPMorgan Chase & Co. assumed coverage on Upstream Bio in a research note on Tuesday, November 5th. They issued an “overweight” rating and a $38.00 target price on the stock.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.